Valuation: Mymetics Corp

Market Cap 4L 4L 4L 3L 6L 4.18Cr 6L 42.3L 16.61L 2.06Cr 16.47L 16.12L 7.09Cr P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 7.21Cr 6.31Cr 5.82Cr 5.37Cr 10Cr 687.86Cr 10Cr 70Cr 27Cr 338.86Cr 27Cr 26Cr 1.16TCr EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-11.43%+44.21% - - 45
-4.14%-8.06%+57.35%+117.24% 5.7TCr
+1.84%+1.65%+76.90%+95.68% 5.36TCr
-3.76%+2.07%+17.78%+458.09% 2.56TCr
-1.91%-2.67%-19.75%-14.90% 2.35TCr
+2.43%+5.86%+46.56%+0.42% 1.94TCr
-3.19%0.00%+33.99%-26.87% 1.81TCr
-6.84%+2.18%+203.03%+348.11% 1.65TCr
+8.74%+10.46%+47.66% - 1.41TCr
-0.95%+1.60%+24.91%+195.86% 1.44TCr
Average -1.96%+1.16%+54.27%+146.70% 2.69TCr
Weighted average by Cap. -1.23%+0.29%+54.80%+137.06%

Financials

2021 2022
Net sales 4L 4L 3L 3L 6L 4.1Cr 6L 41.45L 16.28L 2.02Cr 16.15L 15.79L 6.95Cr 10.28L 9L 8L 8L 14.54L 9.8Cr 14.78L 99.1L 38.92L 4.83Cr 38.6L 37.76L 17Cr
Net income -47.3L -41.37L -38.16L -35.25L -66.88L -45Cr -68L -4.56Cr -1.79Cr -22Cr -1.78Cr -1.74Cr -76Cr -48.05L -42.03L -38.77L -35.8L -67.94L -46Cr -69.08L -4.63Cr -1.82Cr -23Cr -1.8Cr -1.76Cr -78Cr
Net Debt 6.71Cr 5.87Cr 5.41Cr 5Cr 9.49Cr 639.96Cr 9.65Cr 65Cr 25Cr 315.26Cr 25Cr 25Cr 1.08TCr 7.17Cr 6.27Cr 5.78Cr 5.34Cr 10Cr 683.68Cr 10Cr 69Cr 27Cr 336.8Cr 27Cr 26Cr 1.16TCr
Logo Mymetics Corp
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-